Zhangzhou Pientzehuang Pharmaceutical (600436) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was RMB 2.74 billion, down 12.74% year-over-year from RMB 3.14 billion.

• Net profit attributable to shareholders was RMB 743 million, a 25.64% decrease year-over-year.

• Operating cash flow increased 40.84% year-over-year to RMB 1.29 billion.

Financial highlights

• Total profit for Q1 2026 was RMB 876 million, down 25.92% year-over-year.

• Basic and diluted EPS were both RMB 1.23, down from RMB 1.66 in Q1 2025.

• Gross margin and operating profit margin declined compared to the previous year.

• Total assets at quarter-end were RMB 18.38 billion, up 4.70% from year-end 2025.

• Shareholders’ equity increased 4.63% to RMB 15.21 billion.

Outlook and guidance

• No explicit forward-looking guidance provided, but management notes a significant decrease in revenue and profit.